NCT06460844View on ClinicalTrials.gov

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 27, 2024

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2030

Conditions
Retinitis PigmentosaChoroideremia
Interventions
GENETIC

RTx-015

Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.

Trial Locations (4)

15221

RECRUITING

UPMC Vision Institute, Pittsburgh

77401

RECRUITING

Retina Consultants of Texas Research Centers, Bellaire

90211

RECRUITING

Retina Vitreous Associates Medical Group, Beverly Hills

92868

RECRUITING

UCI Alpha Clinic, Orange

All Listed Sponsors
lead

Ray Therapeutics, Inc.

INDUSTRY